Featured Research

from universities, journals, and other organizations

First Report on Worldwide Prevalence of Retinal Vein Occlusion

Date:
February 1, 2010
Source:
American Academy of Ophthalmology
Summary:
Ophthalmologists recognize retinal vein occlusion (RVO), commonly called "eye stroke," as a serious disease and significant cause of blindness. Surprisingly, the magnitude of the problem had been unclear prior to this first report on worldwide RVO prevalence by the International Eye Disease Consortium (IEDC). Based on data from 15 major population studies in the United States, Europe, Asia and Australia, the IEDC estimates that globally, 16.4 million adults are affected by RVO.

Ophthalmologists recognize retinal vein occlusion (RVO), commonly called "eye stroke," as a serious disease and significant cause of blindness. Surprisingly, the magnitude of the problem had been unclear prior to this first report on worldwide RVO prevalence by the International Eye Disease Consortium (IEDC). Based on data from 15 major population studies in the United States, Europe, Asia and Australia, the IEDC estimates that globally, 16.4 million adults are affected by RVO.

For comparison, more than 131 million adults with diabetes worldwide either have diabetic retinopathy or are at risk of developing this potentially blinding disease, according to a 2005 World Health Organization report.

In central and branch retinal vein occlusion (CRVO and BRVO), vision impairment and eye damage occur when the vein becomes blocked, usually by a blood clot. This leads to reduced blood flow, hemorrhage and/or swelling in the retina, the light-sensitive tissue at the back of the eye that receives images and relays them to the optic nerve. An estimated 13.9 million people worldwide are affected by BRVO, and 2.5 million by CRVO, the IEDC report found. Prevalence is similar in men and women and increases with age, probably because of age-related increases in arteriosclerosis, hypertension and glaucoma or elevated intraocular pressure. Although BRVO prevalence appears to be highest in Asians and Hispanics and lowest in whites, the authors say this may reflect varying methodologies or definitions among reviewed studies rather than true ethnic differences.

"We need to understand how hypertension and other cardiovascular risk factors impact BRVO and CRVO, and how glaucoma impacts CRVO, in various ethnic groups and populations so that appropriate preventive and treatment strategies can be designed," said Tien Y. Wong, MD., PhD, lead investigator for the IEDC.

This research was published in the February issue of Ophthalmology, the journal of the American Academy of Ophthalmology.


Story Source:

The above story is based on materials provided by American Academy of Ophthalmology. Note: Materials may be edited for content and length.


Cite This Page:

American Academy of Ophthalmology. "First Report on Worldwide Prevalence of Retinal Vein Occlusion." ScienceDaily. ScienceDaily, 1 February 2010. <www.sciencedaily.com/releases/2010/02/100201113748.htm>.
American Academy of Ophthalmology. (2010, February 1). First Report on Worldwide Prevalence of Retinal Vein Occlusion. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/02/100201113748.htm
American Academy of Ophthalmology. "First Report on Worldwide Prevalence of Retinal Vein Occlusion." ScienceDaily. www.sciencedaily.com/releases/2010/02/100201113748.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins